Get the Stockscreener App
4.10
4.21%
-0.18
Neuphoria Therapeutics Inc stock is traded at $4.10, with a volume of 332.62K.
It is down -4.21% in the last 24 hours and down -78.16% over the past month.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
See More
Previous Close:
$4.28
Open:
$4.22
24h Volume:
332.62K
Relative Volume:
0.23
Market Cap:
$7.71M
Revenue:
$15.66M
Net Income/Loss:
$5.83M
P/E Ratio:
-0.1716
EPS:
-23.8939
Net Cash Flow:
$466.20K
1W Performance:
-9.89%
1M Performance:
-78.16%
6M Performance:
-16.89%
1Y Performance:
+0.00%
1-Day Range:
$4.09
$4.3683
1-Week Range:
$3.93
$4.60
52-Week Range:
$2.90
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Name
Neuphoria Therapeutics Inc
Sector
Industry
Phone
781-439-5551
Address
100 SUMMIT DR, BURLINGTON
Compare NEUP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
4.10 | 10.09M | 15.66M | 5.83M | 466.20K | -23.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-28-23 | Reiterated | Maxim Group | Buy |
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
View All
Neuphoria Therapeutics Inc Stock (NEUP) Latest News
Is Neuphoria Therapeutics Inc. meeting your algorithmic filter criteriaEarnings Performance Report & Precise Swing Trade Entry Alerts - newser.com
Combining price and volume data for Neuphoria Therapeutics Inc.Weekly Loss Report & High Conviction Trade Alerts - newser.com
Neuphoria Therapeutics Inc expected to post a loss of $1.33 a shareEarnings Preview - TradingView
Is Neuphoria Therapeutics Inc. still worth holding after the dipJuly 2025 Catalysts & Fast Gaining Stock Strategy Reports - newser.com
Is Neuphoria Therapeutics Inc. showing signs of accumulationMarket Volume Report & Technical Entry and Exit Tips - newser.com
Will Neuphoria Therapeutics Inc. stock deliver shareholder valueWeekly Trade Summary & Growth Oriented Trading Recommendations - newser.com
What indicators show strength in Neuphoria Therapeutics Inc.Trade Exit Summary & Verified Entry Point Signals - newser.com
What does recent volatility data suggest for Neuphoria Therapeutics Inc.2025 Key Highlights & Technical Pattern Alert System - newser.com
Can Neuphoria Therapeutics Inc. stock hit analyst price targetsGDP Growth & Community Verified Trade Signals - newser.com
What Wall Street predicts for Neuphoria Therapeutics Inc. stock priceWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
Will Neuphoria Therapeutics Inc. stock attract more institutional investors2025 Bull vs Bear & Weekly Breakout Watchlists - newser.com
Neuphoria Therapeutics Inc.’s volatility index tracking explained2025 Growth vs Value & AI Based Buy/Sell Signal Reports - newser.com
Using AI based signals to follow Neuphoria Therapeutics Inc.Trade Risk Summary & Community Trade Idea Sharing - newser.com
How to read the order book for Neuphoria Therapeutics Inc.July 2025 Momentum & Daily Chart Pattern Signals - newser.com
Is Neuphoria Therapeutics Inc. stock a buy before product launchesStop Loss & AI Enhanced Market Trend Forecasts - fcp.pa.gov.br
Does This Valuation Of Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Imply Investors Are Overpaying? - simplywall.st
Why analysts upgrade Neuphoria Therapeutics Inc. stockPortfolio Growth Summary & Expert Approved Momentum Ideas - newser.com
Can Neuphoria Therapeutics Inc. stock sustain institutional interest2025 Breakouts & Breakdowns & Safe Investment Capital Preservation Plans - newser.com
Can Neuphoria Therapeutics Inc. stock maintain operating marginsBear Alert & Weekly Top Gainers Alerts - newser.com
Is Neuphoria Therapeutics Inc. stock attractive after correctionRate Cut & Fast Exit and Entry Trade Guides - newser.com
Will Neuphoria Therapeutics Inc. stock keep outperforming rivalsQuarterly Trade Report & AI Forecasted Entry and Exit Points - newser.com
What valuation multiples suggest for Neuphoria Therapeutics Inc. stockJuly 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
Why hedge funds are buying Neuphoria Therapeutics Inc. stockQuarterly Trade Review & Risk Controlled Daily Plans - newser.com
Can Neuphoria Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Weekly Recap & Community Supported Trade Ideas - newser.com
How Neuphoria Therapeutics Inc. stock performs in interest rate cyclesJuly 2025 Earnings & Fast Moving Stock Watchlists - newser.com
Neuphoria Therapeutics Inc Stock (NEUP) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):